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Abstract 
Microglia are potential targets for therapeutic intervention in neurological and neurodegenerative 
diseases affecting the central nervous system. In order to assess the efficacy of therapies aimed to reduce 
the tissue damaging activities of microglia and/or to promote the protective potential of these cells, 
suitable pre-clinical and clinical tools for the in vivo analysis of microglia activities and dynamics are 
required. The aim of this work was to identify new translational markers of the anti-inflammatory / 
protective state of microglia for the development of novel PET tracers.  
Methods: New translational markers of the anti-inflammatory/protective activation state of microglia 
were selected by bioinformatic approaches and were in vitro and ex vivo validated by qPCR and 
immunohistochemistry in rodent and human samples. Once a viable marker was identified, a novel PET 
tracer was developed. This tracer was subsequently confirmed by autoradiography experiments in 
murine and human brain tissues. 
Results: Here we provide evidence that P2RY12 expression increases in murine and human microglia 
following exposure to anti-inflammatory stimuli, and that its expression is modulated in the reparative 
phase of experimental and clinical stroke. We then synthesized a novel carbon-11 labeled tracer targeting 
P2RY12, showing increased binding in brain sections of mice treated with IL4, and low binding to brain 
sections of a murine stroke model and of a stroke patient.  
Conclusion: This study provides new translational targets for PET tracers for the 
anti-inflammatory/protective activation state of microglia and shows the potential of a rationale-based 
approach. It therefore paves the way for the development of novel non-invasive methodologies aimed to 
monitor the success of therapeutic approaches in various neurological diseases. 
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Introduction 
Microglia are the resident macrophages of the 
central nervous system (CNS). They play a major role 
in maintaining CNS homeostasis by constantly 
monitoring the brain parenchyma to remove cell 
debris, remodeling extracellular matrix, and 
reshaping synapses and neuronal connectivity [1]. 
Microglia are the first responders in case of brain 
injury or infection in which, in the majority of cases, 
they act by eliminating the noxious stimuli via 
phagocytosis in order to prevent damage to the neural 
tissue. Moreover, microglia responses involve the 
secretion of pro- and/or anti-inflammatory cytokines. 
Thus, the activation of microglia upon insult is 
associated with significant morphological and 
immunological changes. Microglial “activation states” 
are grouped into three main categories: the 
resting/surveilling state, the pro-inflammatory, and 
the anti-inflammatory activation states [2]. The 
pro-inflammatory activation state is characterized by 
the production of e.g. interleukin (IL) 1β, tumor 
necrosis factor (TNF) and IL6. It is well-described in 
acute infections, in acute CNS lesions such as stroke 
and in chronic neurodegenerative diseases such as 
Parkinson’s (PD), Alzheimer’s (AD), and amyotrophic 
lateral sclerosis (ALS) [3-5]. Less is known on the 
anti-inflammatory activation state, which is 
associated with attenuated responses to 
pro-inflammatory stimuli, metabolic alterations, 
promotion of tissue repair, extracellular matrix (ECM) 
reconstruction and with neuroprotection [6]. These 
anti-inflammatory features, however, appear to be of 
utmost importance, particularly in 
neuroinflammation-driven pathologies, in which 
microglia potentially have a significant protective 
function [7-11]. As a result, several groups have 
suggested microglia as a potential target for 
therapeutic intervention in neurological and 
neurodegenerative diseases with immunomodulatory 
drugs facilitating microglia transition from a 
pro-inflammatory to an anti-inflammatory activation 
state [12, 13]. A major obstacle in the development of 
such drugs is the lack of efficient tools to measure the 
dynamic changes of microglia activity, especially in 
human CNS pathologies or animal models of disease. 
Such tools are crucial to understand the exact role of 
neuroinflammation in acute CNS diseases and, more 
importantly, in the onset and development of chronic 
CNS disorders [10, 11].  
An excellent imaging technique to study 
dynamic functional changes in vivo is positron 
emission tomography (PET). Currently PET imaging 
of neuroinflammation is hampered by technical (e.g. 
the sensitivity and specificity of the available 
radioligands), and conceptual factors (lack of specific 
markers for microglia activation states). Nonetheless, 
PET imaging of activated microglia, targeting the 18 
kDa translocator protein (TSPO) [14] has provided 
improved understanding of microglial changes in the 
course of pathologies [15], such as neurodegenerative 
diseases [16-19], and mild cognitive impairment in 
specific subsets of patients [19, 20]. Development of 
novel tracers for monitoring of specific microglia 
activation states would be a major advance in the 
field. 
Recent studies in mouse models of 
neuroinflammation [13, 21, 22] have focused on the 
molecular characteristics of anti-inflammatory 
microglia, thus providing novel targets potentially 
applicable to non-invasive preclinical imaging [23]. 
Unfortunately, so far most of the markers identified in 
murine models lack human homologs (e.g., Ym1 and 
Fizz1) [24] or are regulated in a species-specific 
manner (e.g., Arg1) [24]. Among the few biomarkers 
of anti-inflammatory activation that are shared by 
humans and rodents (e.g., CD163, Mrc1 and Tgm2), 
only transglutaminase 2 (TG2) seemed to be a good 
candidate for PET imaging of neuroinflammation, and 
was therefore investigated in detail for the 
development of novel PET tracers [25, 26]. However, 
TG2 does not appear to be suitable for imaging of 
neuroinflammation because of its wide-spread 
expression in many tissues [27].  
The aim of the current study was to identify and 
validate specific molecular markers of 
anti-inflammatory activated microglia for the 
development of novel PET tracers. These novel 
imaging tools will ultimately be used to investigate 
the role of neuroinflammation in neurological 
diseases for diagnostic and prognostic purposes and 
for the development of novel immunomodulatory 
treatments. 
Methods 
Reagents for biology 
Human, mouse and rat recombinant IL4 (rIL4) 
were obtained from PeproTech. Lipopolysaccharide 
(LPS) (isotype 0.111:B4) was obtained from 
Sigma-Aldrich. Unless otherwise specified, chemicals 
were purchased from Merck. 
Reagents and methods for chemistry 
Chemicals were obtained from commercial 
sources and used without further purification. 
Solvents were purchased from Sigma-Aldrich and 
Biosolve and used as received unless stated otherwise. 
Acetonitrile (MeCN) was dried over 3Å molecular 
sieves. Tetrahydrofuran (THF) was first distilled from 
LiAlH4 and then stored on 3Å molecular sieves. 
Reactions were performed at room temperature 
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unless stated otherwise. Reaction progress was 
monitored by thin layer chromatography (TLC) on 
pre-coated silica 60 F254 aluminum plates (Merck). 
Spots were visualized by UV light or staining with 
ninhydrine or KMnO4. Evaporation of solvents was 
performed under reduced pressure at 40 °C using a 
rotary evaporator. Flash column chromatography was 
performed manually on Silica gel 60 Å (Merck) or on a 
Büchi Sepacore system (comprising a C-620 control 
unit, a C-660 fraction collector, two C-601 gradient 
pumps and a C-640 UV detector) equipped with Büchi 
Sepacore prepacked flash columns. Nuclear magnetic 
resonance (NMR) spectroscopy was performed on a 
Bruker Avance 250 (250.13 MHz for 1H and 62.90 
MHz for 13C) or a Bruker Avance 500 (500.23 MHz for 
1H and 125.78 MHz for 13C) with chemical shifts (δ) 
reported in parts per million (ppm) relative to the 
solvent (CDCl3, 1H 7.26 ppm, 13C 77.16 ppm; dimethyl 
sulfoxide (DMSO)-d6, 1H 2.50 ppm, 13C 39.52 ppm). 
Electrospray ionization high resolution mass 
spectrometry (ESI-HRMS) was carried out using a 
Bruker microTOF-Q instrument in positive ion mode 
(capillary potential of 4500 V). Analytical isocratic 
high-performance liquid chromatography (HPLC) 
was performed on a Jasco PU-1580 or PU2080i Plus 
station equipped with a Platinum C18 5 µm (250 × 4.6 
mm) column (Grace) using MeCN/H2O/ 
trifluoroacetic acid (TFA) (45:55:0.1, v/v/v) as eluent 
at a flow rate of 1 mL/min (method A), a Jasco 
UV-2075 Plus UV detector (254 nm) and a NaI 
radioactivity detector (Raytest). Chromatograms were 
acquired with Raytest GINA Star software (version 
5.8). Semi-preparative isocratic HPLC was performed 
on a Jasco PU-1587 station equipped with an Alltima 
C18 5 µm (250 × 10 mm) column (Grace) using 
MeCN/H2O/TFA (55:45:0.1, v/v/v) as eluent at a 
flow rate of 4 mL/min (method B), a Jasco UV-2075 
UV detector (254 nm), a custom-made radioactivity 
detector and Jasco ChromNAV CFR software (version 
1.14.01). Analytical HPLC for metabolite analysis was 
performed with Dionex UltiMate 3000 HPLC 
equipment with Chromeleon software (version 6.8) on 
a Gemini C18 5-µm (10 × 250 mm) column 
(Phenomenex) with gradient and a mixture of MeCN 
(A) and 0.1% TFA in water (B) as eluent according to 
the following scheme (method C): 0 min, 90% B at 0.25 
mL/min; 0.5 min, 90% B at 4 mL/min; 9.0 min, 30% B 
at 4 mL/min; 13.0 min, 30% B at 4 mL/min; 14.0 min. 
90% B at 4.0 mL/min; and 15 min, 90% B at 0.25 
mL/min.  
Primary human macrophage cultures 
Given the lack of gold standard protocols for 
anti-inflammatory activation on human cells in vitro, 
we polarized human macrophages using different 
protocols and characterized resulting activation states 
in terms of target-gene expression. i) Human 
monocytes were isolated from 3 different healthy 
donors by 2-step gradient centrifugation, and 
macrophages were obtained by spontaneously 
differentiating monocytes in RPMI 1640 with 10% FCS 
for 7 days. Macrophages were stained positively for 
intracellular CD68, whereas cell surface CD68 was 
detected in only 10% of cells, indicating a low basal 
activation state (not shown). Resting macrophages 
were incubated with LPS/IFN-γ (1 µg/mL), or rIL4 
(20 ng/mL) and IL13 (5 ng/mL) for 48 h, and then 
processed for RNA preparation. ii) Human monocytes 
were isolated from buffy coats from 3 different 
healthy donors using gradient centrifugation 
followed by plastic adhesion. For differentiation into 
macrophages, the cells were cultivated for 6 days in 
RPMI1640 containing 10% fetal bovine serum (FBS) 
and supplemented for a pro-inflammatory activation 
with granulocyte macrophage colony-stimulating 
factor (GM-CSF) (100 ng/mL) (Gibco) or for an 
anti-inflammatory activation with macrophage 
colony-stimulating factor (M-CSF) (100 ng/mL) 
(Gibco). The actual polarization into a pro- or 
anti-inflammatory activation type was done for 48 h 
in RPMI (2.5% FBS) with GM-CSF + 10 ng/µL LPS 
(Sigma-Aldrich) or with M-CSF + 20 ng/µL rIL4 
(Gibco). Cells were then processed for RNA 
preparation. 
Primary human microglia cultures 
The temporal neocortex was obtained from four 
epilepsy patients undergoing anterior temporal 
lobectomies. During the operation, part of the 
temporal neocortex was removed before performing 
an amygdalohippocampectomy. In all subjects, the 
amygdala and hippocampus were determined to be 
the epileptogenic zone during the epilepsy surgery 
evaluation. Histopathological preparations of 
neocortex were normal in all subjects. Written 
informed consent was obtained from all patients 
before the surgery. All studies were in accordance 
with the protocol approved by the Rigshospitalet's 
Ethical Committee in the Capital Region of Denmark 
(H‐2‐2011‐104). Following surgical resection, tissue 
was transported to the research facility. 
Approximately 1–2 g of tissue was washed in Hank’s 
Balanced Salt Solution (HBSS), and meninges and 
visible blood vessels were removed. Tissue was diced 
into pieces of approximately 1 mm3 using a sterile 
scalpel and transferred to a 50 mL falcon tube 
containing 10 mL enzyme dissociation mix (10 U/mL 
DNase (Invitrogen) and 2.5 U/mL papain 
(Worthington) in Hibernate-A medium (Gibco) per 
gram of tissue for 10 min at 37 °C with gentle rotation. 
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The tissue was removed from the incubator, gently 
triturated to aid digestion and returned to the 
incubator for 10 min. Dissociation was slowed by 
adding an equal volume of Dulbecco’s Modified Eagle 
Medium (DMEM): Nutrient mixture F-12 
(DMEM/F12; Gibco) with 1% B27 (Gibco) and the cell 
suspension was passed through a 70 μm cell strainer 
(Bector Dickinson). Cells were centrifuged at 160 ×g 
for 10 min, the supernatant discarded and 
resuspended in 20 mL neural precursor cell (NPC) 
proliferation media (DMEM/F12 with 1% B27, 1% 
GlutaMAX (Gibco,), 1% penicillin-streptomycin- 
glutamine (PSG; Gibco), 40 ng/mL fibroblast growth 
factor-2 (FGF-2; Peprotech), 40 ng/mL epidermal 
growth factor (EGF; Peprotech) and 2 μg/mL heparin 
(Sigma). The cell suspension was transferred to 
24-well plates (Nunc) and incubated overnight at 
37 °C with 95% air/5% CO2. The following day, the 
plates were tapped firmly to remove non-adherent or 
loosely-adherent cells. The adherent primary human 
microglia were cultured in high glucose DMEM 
containing 2 mM glutamine, 1 mM pyruvate and 10% 
FBS. Stimulation with 1 µg/mL LPS or 20 ng/mL IL4 
and 5 ng/mL IL13 was started on day 6 post-isolation. 
The old medium in all wells was completely removed 
and fresh medium was added containing the desired 
amount of each stimulant. The cells used as controls 
received the regular medium without any stimuli. The 
cells were harvested 48 h later in 350 µL RLT buffer 
(Qiagen) for RNA preparation. 
Microglia sorting from murine tissue 
After 16 h of rIL4 or vehicle treatment, brains 
were dissected and washed in HBSS (Life 
Technologies); after removing the meninges, cortices 
from five mice were pooled as a single experimental 
group. Enzymatic cell dissociation was performed 
using Neural Tissue Dissociation Kit P (Miltenyi 
Biotec), following a modified version of the protocol 
supplied by the manufacturer. Briefly, after enzymatic 
digestion with papain, samples were dissociated 
mechanically, homogenized, and filtered through a 
40-μm cell strainer. After extensive washes in HBSS, 
myelin was removed by centrifuging the dissociated 
brain cells, which had previously been suspended in 
10 mL of cold 0.9 M sucrose solution, at 850 ×g and 
4 °C for 10 min without braking. Floating myelin and 
the supernatant were discarded, and cells were 
processed for microglia magnetic sorting by 
incubating with CD11b MicroBeads (diluted 1:10 in 
PBS + 0.05% bovine serum albumin (BSA); Miltenyi 
Biotec) for 15 min at 4 °C. After washings, cells were 
suspended in 500 μL of PBS + 0.05% BSA and applied 
to a magnetic column to purify CD11b+ cells, namely 
microglia. Immediately after isolation of microglia, 
cells were processed for RNA preparation. 
Incubations with FITC-antiCD11b antibody (Miltenyi 
Biotec) and flow cytometric analyses were performed 
separately on dissociated brain cells as well as on 
CD11b-immunosorted cells to calculate recovery and 
purity. The protocol allowed us to obtain 80 to 85% 
recovery of CD11b-positive microglial cells, that is, 
10-12% of the total brain cell population after tissue 
dissociation and myelin removal, with 90 to 95% 
purity after magnetic immunosorting. 
RNA and cDNA preparation 
Cortex, hippocampus and hypothalamus were 
dissected from the mouse brain and processed for 
RNA purification. The brain areas were homogenized 
using steel beads and a TissueLyser (Qiagen) at 28 Hz 
for three cycles of 20 s, followed by 30 s on ice and in 
RLT buffer. Then total RNA was purified using an 
RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions including a step with 
deoxyribonuclease incubation. Thereafter, 1 μg RNA 
was used for cDNA preparation using 8 U/μL of 
Moloney murine leukemia virus reverse transcriptase 
(Promega) in a final volume of 25 μL; the reaction was 
performed at 37 °C for 1 h, and the enzyme 
inactivated at 75 °C for 5 min. Isolated murine 
microglia, human macrophages and human 
microglial cells were homogenized in RLT buffer and 
total RNA was purified using an RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions 
including a step with deoxyribonuclease incubation. 
Thereafter, 500 ng RNA was used for cDNA 
preparation using 8 U/μL of Moloney murine 
leukemia virus reverse transcriptase (Promega) in a 
final volume of 25 μL; the reaction was performed at 
37 °C for 1 h, and the enzyme inactivated at 75 °C for 5 
min. Control reactions without the addition of the 
reverse transcription enzyme were performed (data 
not shown). 
Real-time PCR 
A 1:16 cDNA dilution was amplified using SYBR 
technology. The PCR was carried out in triplicate on a 
96-well plate using GoTaq®qPCR Master Mix 
technology (Promega) according to the 
manufacturer’s protocol using 7900HT fast real time 
PCR system (Applied Biosystems, Life Technologies) 
with the following thermal profile: 2 min at 95 °C; 40 
cycles, 15 s at 95 °C, 15 s at 60 °C. Gene expression of 
target genes was assessed for murine chitinase-like 3 
(Chi3l3, or Ym1; forward primer, 5′-GAAGGAGCCAC 
TGAGGTCTG-3′; reverse primer, 5′-GAGCCACTGA 
GCCTTCAAC-3′), murine P2ry12 (forward primer, 
5′-AACTCGCAGGTTCTGGCTGG-3′; reverse primer, 
5′-AAGCCCCGAGTCCTAGGTT-3′), human P2RY12 
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(forward primer, 5′-TTCAGCTATTGGACGCGAGG- 
3′; reverse primer, 5′-GAATCTGACACCCAGCGG 
AA-3′), murine Ramp1 (forward primer, 5′-ACCAA 
CTATTGCTTCAGCTTCAGCTCCAC-3′; reverse 
primer, 5′-GATCCACTTCCAACCCAGGTC-3'), 
human RAMP1 (forward primer, 5′-TGCCACC 
TTTTGACAGTGATG-3′; reverse primer, 5′-GCTGCG 
AGATTTGAAGCTGG-3′), murine Calcrl (forward 
primer, 5′-CCTATGTCTCAGCCTCTTCTC-3′; reverse 
primer 5′-CTCTTGCTTATCCCCTCTTCC-3′), human 
CALCRL (forward primer, 5′-GACCACGGAGGCA 
GGGACAC-3′; reverse primer 5′-CTTCCCGTT 
GGGTGCTCGGC-3′) and for the reference gene 36B4 
(forward primer, 5′-GGCGACCTGGAAGTCCAACT- 
3′; reverse primer, 5′-CCATCAGCACCACGGCCT 
TC-3′). The reactions were carried out according to the 
manufacturer's protocol using a 7900HT fast real time 
PCR system (Applied Biosystems), and the results 
were analyzed using the 2-ΔΔCt method. For the 
samples of GM/M-CSF-treated human macrophages, 
TaqMan RT-PCR was used for quantitative gene 
expression analyses. RNA was isolated with an 
RNeasy Mini Plus Kit (Qiagen) and transcribed to 
cDNA with a Reverse Transcription System 
(Promega). Amplification of technical duplicates (each 
containing 10 ng reverse transcribed RNA) was done 
using the GoTAQ Probe qPCR Master Mix (Promega) 
with a two-step cycling protocol (95 °C for 15 s, 60 °C 
for 60 s; 40 cycles) in a Bio-Rad CFX 96 Cycler. The 
following gene expression assays (all from Integrated 
DNA Technologies) were used: P2RY12 
(Hs.PT.58.39733142), RAMP1 (Hs.PT.58.3071042), and 
CALCRL (Hs.PT.58.24834078); and the housekeeping 
genes UBC (Hs.PT.39a.22214853) and POLR2A 
(Hs.PT.39a.19639531) for data normalization. 
Normalized relative quantities of RNA were 
calculated with qBase Plus (Biogazelle) using geNorm 
algorithms for multi-reference gene normalization. 
Animals 
C57BL/6 male mice with an age of 4 months 
were supplied by Charles River Laboratories. Healthy 
male Wistar and Sprague-Dawley rats were obtained 
from Harlan and Janvier Labs, respectively. All 
animals were allowed free access to food and water 
and were kept in temperature-controlled facilities on a 
12-h light and dark cycle at constant temperature (23 
°C) and relative humidity (40%). Mice were 
group-housed in the animal care facility of the 
Department of Pharmacological and Biomolecular 
Sciences at the University of Milan and the European 
Institute for Molecular Imaging of the University 
Hospital Münster. Rats were group-housed in the 
animal care facility of the Department of the 
Radionuclide Center of the VU University Medical 
Center Amsterdam. Animal studies were approved 
by the animal ethics committees of local authorities 
and were conducted in accordance with the Directives 
of the European Union on animal ethics and welfare. 
Intracerebroventricular injections 
Intracerebroventricular (icv) injections in 
C57BL/6 male mice with an age of 4 months were 
made as previously described [28]. Briefly, mice were 
deeply anesthetized with a subcutaneous injection of 
a mixture of ketamine and xylazine (78 and 6 mg/kg, 
respectively) placed on a warming pad and 
positioned on a stereotactic frame for surgery. 
Injections in the third cerebral ventricle (icv) were 
performed according to specific stereotaxic 
coordinates (bregma, -0.25 mm; lateral, 1 mm; depth, 
2.25 mm), as previously described [28]. During this 
procedure rIL4 was injected solved in 3 μL of 0.9% 
NaCl using a 26S-gauge Hamilton syringe. Infusions 
were made at a rate of 0.1 μL/3 s. The needle was kept 
in place for 30 s after the injection and then removed 
slowly. Animals injected with the same volume of 
vehicle (0.9% NaCl) alone were used as controls. The 
skin incision was closed with a suture and animals 
were allowed to recover for 16 h before sacrifice by a 
lethal ketamine and xylazine solution (150 and 12 
mg/kg, respectively). For RNA quantification 
(NaCl-injected, n = 3; IL4-injected, n = 3), the right 
cerebral cortex, hippocampus and hypothalamus, 
contralateral to the injection site, were collected, 
immediately frozen on dry ice, and stored at -80 °C 
until RNA preparation. For autoradiography 
(NaCl-injected, n = 4; IL4-injected, n = 4), whole brains 
were snap-frozen in liquid nitrogen and stored at 
-80 °C. 
Middle cerebral artery occlusion in rats 
Male Sprague-Dawley rats (n = 6) weighing 
200-250 g underwent permanent middle cerebral 
artery occlusion (pMCAO), as previously described 
[29]. Briefly, rats were intraperitoneally anesthetized 
with ketamine (90 mg/kg) and xylazine (10 mg/kg) 
and the temporalis muscle was dissected; after 
craniectomy, the right middle cerebral artery (MCA) 
was exposed and coagulated by means of 
microbipolar coagulation (SAMED MB122) to occlude 
it permanently from its stem to the lenticulostriate 
branch. It was then divided to ensure successful 
occlusion. The retracted temporalis muscle was 
allowed to fall back into place and sutured. Rats were 
allowed to recover from anesthesia in warmed cages 
for 2 h to hold the body temperature at 37 °C. After 48 
h, rats were anaesthetized and transcardially perfused 
first with phosphate-buffered saline (PBS) and then 
with 4% para-formaldehyde (PFA). Brains were 
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collected, shortly post-fixed in 4% PFA, cryoprotected 
in 30% sucrose until precipitation at 4 °C and then 
frozen at -80 °C. 
Middle cerebral artery occlusion in mice 
Male C57BL/6 (n = 6) mice underwent transient 
middle cerebral artery occlusion (tMCAO), as 
previously described [30]. In brief, mice were 
anesthetized with 1.5% isoflurane (Abbott Animal 
Health) in a 2:1 air and oxygen mixture. A 7-0 
monofilament (tip diameter 190 to 200 μm, coating 
length 2 to 3 mm, 70SPRePK5, Doccol), was inserted 
into the common carotid artery, positioned at the 
MCA for 30 min and carefully retracted afterwards. 
Successful occlusion and reperfusion was monitored 
intraoperatively using a Laser Doppler probe 
(Perimed Instruments). During the procedures, body 
temperature was maintained at physiological levels 
with a custom-built heating pad. 3, 7, 10 days (n = 
2/time point) after stroke induction mice were 
sacrificed and brains harvested as described above. 
Magnetic resonance imaging analysis 
Brain infarct size was visualized by T2-weighted 
MR imaging at 48 h after MCAO using a 4.7 T, vertical 
super wide bore magnet of a Bruker Avance II 
spectrometer with micro imaging accessory. Rats 
were anesthetized with 1.5% isoflurane in 2 L/min of 
a mixture of N2/O2 (70%/30%), fixed on the holder 
and placed into the 6.4 cm diameter birdcage coil. A 
3-orthogonal-plane, gradient echo scout acted as a 
geometric reference for locating the olfactory bulb. 
The T2W images were obtained with a RARE 
sequence with an equivalent TE of 80 ms, a TR of 3 s, a 
refocusing flip angle of 180°, and a FOV of 4.0 × 4.0 
cm2; 16 contiguous coronal slices with a thickness of 
1.0 mm, a matrix size of 128 × 128, and 12 signal 
averages were recorded for a total scan time of 4 min 
and 48 s. Lesions were identified as areas of high 
signal intensity [31]. 
Intrastriatal injections of rat IL4 
Healthy male Wistar rats (350 ± 89 g, 7-9 weeks 
old) were anaesthetized with 2.5% isoflurane in 100% 
O2 and positioned in a stereotactic frame for injection 
of 1 μg rat rIL4 (1 µg/µL in PBS); n = 3) or vehicle (PBS 
only; n = 3). Injection was done into the right striatum 
(bregma: +1.0 mm, lateral: 3.0 mm, depth: 5.0 mm 
from the surface of the brain) using a 1 µL Hamilton 
microsyringe and a micropump (Micro4 Controller; 
WPI). The infusion rate was set to 500 nL/min and the 
syringe was left in place after injection for 10 min 
before it was retracted slowly. The site of incision was 
then cleaned and sutured using 4.0 braided silk before 
being disinfected. Animals were maintained 
normothermic during the surgery using a heating 
blanket (Homeothermic Blanket Control Unit; 
Harvard Apparatus). Animals were euthanized one 
day after intrastriatal rIL4 injection. Brains were 
rapidly excised and frozen in isopentane pre-cooled in 
liquid nitrogen (-50 °C) and then stored at -80 °C until 
use. 
Human brain tissue 
The brain of a patient who died 18 days after 
stroke onset at the Stroke Unit of the Hospital Clinic 
of Barcelona was used after obtaining written consent 
from the relatives or legal representatives for tissue 
removal after death at the Neurological Tissue Bank 
of the Biobank-Hospital Clinic-Institut 
d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS). The Ethics Committee of this Hospital 
approved the study.  
Immunohistochemistry 
Immunohistochemistry staining on rat brain 
sections was performed at day 1 after rIL4 
administration. Animals were euthanized and their 
brains rapidly excised and frozen in isopentane 
pre-cooled in liquid nitrogen (-50 °C) and then stored 
at -80 °C until use. 10 µm-thick frozen transversal 
brain sections were cut at -20 °C using a cryostat 
(Leica). Rat brain sections were fixed in 4% PFA for 15 
min. PFA blockage was performed with NH4Cl (50 
mmol/L) in PBS for 5 min and tissue permeabilization 
was performed with methanol-acetone 1:1 (-20 °C) 
and 0.1% Triton in PBS for 5 min at room temperature. 
Sections were washed with PBS after every step. The 
sections were saturated with a solution of 5% 
BSA/0.5% Tween in PBS for 15 min at room 
temperature to block nonspecific binding. Sections 
were incubated for 1 h at room temperature with 
primary antibodies in 5% BSA/0.5% Tween in PBS. 
Sections were stained for P2RY12 with rabbit 
anti-P2RY12 (1:100; AnaSpec, #55043A), for CD11b 
with mouse anti-CD11b (1:100; Serotec, #MCA275R), 
for Iba1 with goat anti-Iba1 (1:100, Abcam, #5076) and 
for mannose receptor with rabbit anti-CD206 (1:100, 
Abcam, #64693). The sections were then washed (3 × 5 
min) in PBS and incubated for 30 min at room 
temperature with secondary antibodies Alexa Fluor 
488 nm donkey anti-rabbit IgG, Alexa Fluor 546 nm 
donkey anti mouse, and Alexa Fluor 546 nm donkey 
anti-goat IgG (1:1000; Invitrogen, #A-21206, #A-10036 
and #A-11056, respectively) in 5%BSA/0.5% Tween 
0.5% in PBS, and then washed again (3 × 5 min) in 
PBS. Specificity of the CD206 and P2RY12 antibodies 
was tested using controls omitting the first antibodies. 
Sections were mounted with a 4,6-diamidino-2- 
phenylindole (DAPI) Prolong Antifade Kit (Molecular 
Probes, Life Technologies,).  
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Chemistry 
Ethyl 6-(3-((tert-butoxycarbonyl)amino)azetidin-1- 
yl)-5-cyano-2-methylnicotinate (2) 
Ethyl 6-chloro-5-cyano-2-methylnicotinate (1; 
0.33 g, 1.49 mmol) and 3-(Boc-amino)-azetidine (0.31 
g, 1.80 mmol) were dissolved in 1,2-dichloroethane (4 
mL) and N,N-diisopropylethylamine (DiPEA; 0.6 mL, 
3.4 mmol) was added. After stirring at 60 °C for 1 h, 
the reaction mixture was concentrated in vacuo and 
the residue was dissolved in ethyl acetate (EtOAc; 10 
mL) and washed twice with saturated aqueous 
NaHCO3 (8 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. Flash column 
chromatography (EtOAc/n-hexane 1:6) was 
performed to obtain ethyl 6-(3-((tert- 
butoxycarbonyl)amino)azetidin-1-yl)-5-cyano-2-meth
ylnicotinate (2) in 32% yield (0.17 g, 0.47 mmol). 
Rf value: 0.14 (EtOAc/n-hexane 1:6), 0.64 
(CH2Cl2/MeOH 95:5); 1H NMR (250.13 MHz, CDCl3) 
δ 8.27 (s, 1H, CHAr), 5.28-5.33 (m, 1H, CHazetidine), 
4.68-4.75 (m, 2H, CH2 (azetidine)), 4.31 (q, 2H, J = 7.1 Hz, 
CH2 (ester)), 4.21-4.27 (m, 2H, CH2 (azetidine)), 2.71 (s, 3H, 
CH3 (pyridine)), 1.48 (s, 9H, 3x CH3), 1.39 (t, 3H, J = 7.1 
Hz, CH3 (ester)); 13C NMR (125.80 MHz, CDCl3) δ 208.68, 
165.38, 164.86, 161.23, 164.86, 146.20, 117.17, 104.83, 
86.65, 60.89, 59.25, 41.40, 28.29, 25.72, 14.29; 
ESI-HRMS: calculated for C18H24N4O4: 360.18; found 
383.1712 [M+Na]+. 
Ethyl 6-(3-aminoazetidin-1-yl)-5-cyano-2- 
methylnicotinate (3) 
Ethyl 6-(3-((tert-butoxycarbonyl)amino)azetidin- 
1-yl)-5-cyano-2-methylnicotinate (2; 1.3 g, 3.6 mmol) 
was dissolved in CH2Cl2 (24 mL). A 4 M solution of 
HCl in 1,4-dioxane (18 mL, 72 mmol) was added 
slowly and the reaction mixture was stirred for 30 
min. The reaction mixture was then concentrated in 
vacuo to afford a white solid, which was dissolved in 
CH2Cl2 (10 mL) and washed with 1 M aqueous 
NaHCO3 (15 mL). The organic layer was separated 
and the water layer was extracted with CH2Cl2 (3 × 15 
mL). Combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. Flash column 
chromatography was performed (2-4% MeOH in 
CH2Cl2) to obtain ethyl 6-(3-aminoazetidin-1-yl)-5- 
cyano-2-methylnicotinate (3) in 87% yield (0.8 g, 3.1 
mmol). 
Rf value: 0.34 (CH2Cl2/MeOH 95:5); 1H NMR 
(500.23 MHz, CDCl3) δ 8.25 (s, 1H, CHAr), 4.66 (m, 2H, 
CH2 (azetidine)), 4.32 (q, 2H, J = 6.9 Hz, CH2 (ester)), 
3.98-4.05 (m, 3H, CH2 + CHazetidine), 2.70 (s, 3H, CH3 
(pyridine)), 1.38 (t, 3H, J = 7.2 Hz, CH3 (ester)); 13C NMR 
(125.80 MHz, CDCl3) δ 165.38, 164.94, 157.95, 146.29, 
117.43, 113.72, 86.41, 61.82, 60.84, 43.48, 25.78, 14.34; 
ESI-HRMS: calculated for C13H16N4O2: 260.13; found 
261.1410 [M+H]+. 
Ethyl 6-(3-(3-((5-chlorothiophen-2-yl)sulfonyl)ureido) 
azetidin-1-yl)-5-cyano-2-methylnicotinate (5) 
Chlorosulfonyl isocyanate (0.3 mL, 4.4 mmol) 
was added to a solution of 5-chlorothiophene- 
2-sulfonamide (0.5 g, 2.5 mmol) in anhydrous 
1,2-dichlorobenzene (20 mL) under an argon 
atmosphere and the reaction mixture was stirred at 
160 °C for 3 h. Thereafter, the reaction mixture was 
cooled to room temperature, decanted and 
concentrated in vacuo at 70 °C. The oily residue was 
dissolved in anhydrous acetonitrile (MeCN, 20 mL) 
and added as obtained to a solution of ethyl 
6-(3-aminoazetidin-1-yl)-5-cyano-2-methylnicotinate 
(3; 0.55 g; 2.11 mmol) in anhydrous MeCN (20 mL) 
and subsequently stirred for 16 h. The precipitate was 
then collected by filtration and washed with MeCN, 
MeOH and n-hexane to obtain ethyl 
6-(3-(3-((5-chlorothiophen-2-yl)sulfonyl)ureido)azetid
in-1-yl)-5-cyano-2-methylnicotinate (5) in 45% as a 
light grey solid (0.49 g, 0.94 mmol).  
Rf value: 0.23 (CH2Cl2/MeOH 95:5); 1H NMR 
(500.23 MHz, DMSO-d6) δ 11.44 (br s, 1H, NH), 8.29 (s, 
1H, CHAr), 7.63 (d, 1H, J = 4.1 Hz, CHthiophene), 7.46 (br 
s, 1H, NH), 7.27 (d, 1H, J = 4.1 Hz, CHthiophene), 
4.46-4.55 (m, 3H, CH + CH2 (azetidine)), 4.25 (q, 2H, J = 7.2 
Hz, CH2 (ester)), 4.13-4.17 (m, 2H, CH2 (azetidine)), 2.61 (s, 
3H, CH3 (pyridine)), 1.30 (t, 3H, J = 7.2 Hz, CH3 (ester)); 13C 
NMR (125.80 MHz, DMSO-d6) δ 164.48, 164.31, 157.86, 
151.30, 146.02, 138.94, 136.20, 133.36, 127.67, 117.06, 
113.52, 86.30, 60.74, 40.48, 25.51, 14.25; ESI-HRMS: 
calculated for C18H18ClN5O5S2: 483.04; found 484.0542 
[M+H]+. 
5-chlorothiophene-2-sulfonyl azide (6) 
Sodium azide (6.4 g, 99 mmol) was dissolved in 
H2O/CH2Cl2 (2:3, 10 mL) and cooled to 0 °C. 
Trifluoromethanesulfonic anhydride (3.4 mL, 20 
mmol) was slowly added. After 3 h, the organic layer 
was separated and the water layer was extracted 
twice with CH2Cl2 (4 mL). The combined organic 
layers were washed with saturated aqueous Na2CO3 
(2 × 10 mL) and added to a solution of 
5-chlorothiophene-2-sulfonamide (0.98 g, 4.9 mmol), 
potassium carbonate (1.37 g, 9.9 mmol) and 
copper(II)sulfate (0.07 g, 0.30 mmol) in H2O/MeOH 
(1:2, 9 mL). After stirring for 16 h, the reaction mixture 
was concentrated in vacuo. H2O (10 mL) was added 
and upon acidification of the solution with 
concentrated HCl to pH 1, the solution turned from 
light blue to colorless. The solution was extracted with 
EtOAc (4 × 10 mL). The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Flash 
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column chromatography was performed (0.1% MeOH 
in CH2Cl2) to obtain 5-chlorothiophene-2-sulfonyl 
azide (6) as a brown oil in 88% yield (0.98 g, 4.4 
mmol). 
Rf value: 0.93 (CH2Cl2/MeOH 99:1); 1H NMR 
(500.23 MHz, CDCl3) δ 7.63 (d, 1H, J = 4.1 Hz, CH), 
7.06 (d, 1H, J = 4.1 Hz, CH); 13C NMR (125.80 MHz, 
CDCl3) δ 141.12, 135.70, 134.33, 127.46 
Radiochemistry  
Ethyl 6-(3-(3-((5-chlorothiophen-2-yl)sulfonyl) 
[11C]ureido)azetidin-1-yl)-5-cyano-2-methylnicotinate 
([11C]5) 
[11C]CO2 was produced by a 14N(p,α)11C nuclear 
reaction performed in a 0.5% O2/N2 gas mixture using 
an IBA Cyclone 18/9 cyclotron (IBA). [11C]CO2 was 
passed over a gas purifier column (400 × 4 mm, silica 
gel, 100/80 mesh) using helium flow (20 mL/min) 
and subsequently reduced to [11C]CO by passing over 
molybdenum (Sigma Aldrich, < 150 µm, 99.99%) at 
850 °C. Unreacted [11C]CO2 was trapped on an 
ascarite column and [11C]CO was trapped on a silica 
trap (1 mg silica gel, 100/80 mesh) at -196 °C. To 
release [11C]CO, the trap was heated and [11C]CO was 
subsequently transferred to a capped reaction vial 
containing precursor 3 (5 mg, 19 µmol), precursor 6 
(2.5 µL, 19 µmol), chloro(1,5-cyclooctadiene) 
rhodium(I) dimer (1 mg, 2 µmol) and 
triphenylphosphine (3 mg, 11 µmol) in 0.7 mL of dry 
THF, using xenon (2 mL/min) as carrier gas [32]. The 
reaction mixture was heated at 100 °C for 5 min, after 
which remaining azide precursor 6 was instantly 
reduced by addition of a solution of 
tris(2-carboxyethyl)phosphine (TCEP; 10 mg, 40 µmol) 
in water (0.1 mL). THF was evaporated by heating the 
reaction mixture to 120 °C for 2 min. The reaction 
mixture was then diluted with 2 mL of eluent 
(MeCN/H2O/TFA, 55:45:0.1, v/v/v) and purified by 
semi-preparative HPLC (method B). The fraction 
containing [11C]5 (tR = 16 min) was collected, diluted 
with 40 mL of water and trapped on a Sep-Pak Plus 
tC18 cartridge (Waters), preconditioned with 1 mL of 
ethanol and 10 mL of water. The cartridge was 
washed with 20 mL of water and subsequently [11C]5 
was eluted with 1 mL of EtOH and diluted with 5 mL 
of 7.09 mM NaH2PO4 in saline. For in vivo studies, 
formulated [11C]5 was diluted further with saline to 
contain ≤ 10% of EtOH. [11C]5 was obtained in a 
decay-corrected radiochemical yield (RCY) of 10 ± 2% 
(n = 6) from end of bombardment (EOB) with a 
radiochemical purity > 98%, a molar activity (Am) of 
79 ± 32 GBq/µmol (n = 6) at end of synthesis and an 
overall synthesis time of 45-50 min. The identity of the 
product was confirmed with analytical HPLC by 
co-injection of the product and non-labeled 5 (method 
A, tR = 12 min). 
Determination of LogDoct,7.4 
The distribution of [11C]5 between 1-octanol and 
0.2 M phosphate buffer (pH = 7.4) was measured at 
room temperature. Briefly, 1 mL of a 20 MBq/mL 
solution of [11C]5 in 0.2 M phosphate buffer (pH = 7.4) 
was mixed with 1 mL of 1-octanol for 1 min using a 
vortex mixer. After a settling period of 30 min, three 
samples of 100 μL were taken from both layers. To 
determine the recovery (> 97%), three samples of 
100 μL were taken from the 20 MBq/mL solution. All 
samples were counted for radioactivity Wallac 
Universal Gammacounter 1282 (PerkinElmer). The 
LogDoct,7.4 value was calculated according to 
LogDoct,7.4 = 10Log(Aoct/Abuffer), where Aoct and 
Abuffer represent average radioactivity counts of the 
three 1-octanol and the three buffer samples. Results 
are presented as mean ± standard deviation (SD). 
In vitro autoradiography 
Snap-frozen icv-injected and MCAO mouse 
brains were cut on a Leica CM3050 S cryostat (Leica 
Biosystems) at -19 °C in sections of 20 µm, 
thaw-mounted on SuperFrostTM Plus (Thermo Fisher 
Scientific) object glasses, dried overnight on silica at 4 
°C and then stored at -20 °C until use. Snap frozen 
human post-mortem brain tissue was cut on a cryostat 
at -15 °C in sections of 20 µm, thaw-mounted on 
SuperFrostTM Plus Gold (Thermo Fisher Scientific) 
object glasses and left in a storage box containing 
silica at room temperature for 1 h before drying 
overnight on silica at 4 °C, after which the sections 
were stored at -20 °C until use. Upon use, sections 
were thawed to room temperature for 1 h before 
washing the sections in 5 mM Tris-HCl buffer (pH 7.4) 
at room temperature (3 × 5 min). Sections were dried 
in a cold stream of air before incubation (30 min) with 
5 mM Tris-HCl buffer (pH 7.4) containing either [11C]5 
(10 nM) alone or [11C]5 (10 nM) and Ticagrelor (10 
µM). After incubation, sections were washed (3 × 1.5 
min) in ice-cold 5 mM Tris-HCl buffer (pH 7.4) 
followed by a dip in ice-cold demineralized water. 
Sections were dried in a stream of air and then 
exposed to a storage phosphor screen (BAS-IP SR 2040 
E, GE Healthcare Europe) and the screen was read out 
on a Typhoon FLA 7000 phosphor imager (GE 
Healthcare Europe). After exposure, sections were 
stored at -80 °C for immunohistochemical staining 
(IHC). Obtained images were analyzed and quantified 
using ImageQuantTL Analysis Toolbox (version 8.1, 
GE Healthcare). A region of interest (ROI) was 
defined around the entire section, except for the 
MCAO mouse brains, where a ROI was defined 
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around each hemisphere. Statistical analysis of 
quantified autoradiography (unpaired t test, 
two-tailed) was performed with GraphPad Prism 
(Version 5.02, GraphPad Software). For 
immunofluorescence staining on MCAO mouse brain 
sections and human post-mortem sections used for 
autoradiography, slides were dried and kept at -80 °C 
until staining. Slides were brought to room 
temperature and fixed with cold acetone for 10 min. 
Then sections were blocked with PBS/1% BSA for 1 h 
at room temperature and incubated with rabbit 
anti-P2RY12 (Anaspec) and mouse anti-MHCII (clone 
LN3, Thermofisher) in PBS/1% BSA overnight at 4 °C. 
Slides were washed 3 × 5 min with PBS/0.05% 
Tween-20 and incubated with goat anti-rabbit 
IgG-Alexa488, goat anti-mouse IgG-Alexa555 and 
DAPI in PBS/1% BSA for 1 h at room temperature. 
Sections were then washed 3 × 5 min with PBS/0.05% 
Tween-20 and coverslips were mounted with Mowiol 
mounting media. Fluorescence images were acquired 
using a Leica DM6000 microscope equipped with a 
motorized stage. Whole-slide low-zoom images were 
acquired using ×10 objective and merged by tile 
stitching to get the final image. For fluorescence 
quantification and comparison, sections were stained 
in a single run and images were collected in a single 
session with the same exposure time between 
different areas and different slides. Images were 
analyzed using Leica LAS AF. Multiple regions of 
interest were draw on the sections and fluorescence 
intensity was quantified. Areas with obvious 
non-specific binding (folding of the section) were 
excluded from quantification. 
Ex vivo biodistribution 
Healthy male Wistar rats (210-275 g, 6-8 weeks 
old, obtained from Harlan) were injected with 30 ± 13 
MBq (at start of the experiment) of [11C]5 (corresponds 
with 0.24 ± 0.07 µg of non-labeled 5) in the tail vein 
under isoflurane anesthesia. Rats were sacrificed and 
dissected at 5 and 15 min post injection (n = 4 for 5 
min, n = 3 for 15 min). Blood, heart, lungs, liver, 
kidneys, spleen and brain were collected, weighed 
and counted for radioactivity in a Wallac Universal 
Gammacounter 1282 (PerkinElmer). Biodistribution 
data were expressed as percentage injected dose per 
gram tissue (%ID/g). 
Metabolite analysis 
Healthy male Wistar rats (230-250 g, 6-8 weeks 
old, obtained from Harlan) were injected with 51 ± 2 
MBq (at start of experiment) of [11C]5 in the tail vein 
under isoflurane anesthesia. Rats were sacrificed at 15 
min (n =3) after tracer injection. Blood samples were 
obtained, and the brain was removed. Blood samples 
were collected in heparin tubes (BD Vacutainer NH 
119 I.U., 7 mL, BD Vacutainer Systems) and 
centrifuged at 2,600 rcf for 5 min at 4 °C (Hettich 
Universal 32). The brain was put in a falcon tube 
containing saline (5 mL) and homogenized with a 
disperser (IKA T18 B Ultra-Turrax, IKA®-Werke) 
before centrifugation (5 min, 2,600 rcf, 20 ºC, Hettich 
Universal 32). Plasma and brain supernatant were 
separated from blood cells and brain precipitate, 
respectively. Plasma was loaded onto a tC18 Sep-Pak 
(Waters), followed by washing with 10 mL of water to 
obtain the polar fraction. The non-polar fraction was 
then eluted with 1.5 mL of MeOH and 1.5 mL of 
water. All separate fractions were counted for 
radioactivity in a Wizard Gammacounter 1470 or 2480 
(Wallac/PerkinElmer) and the non-polar fraction of 
plasma and brain supernatant was further analyzed 
by HPLC using method C. Percentages are expressed 
as mean ± SD. 
Statistical evaluation 
All groups were randomly assigned, and data 
analysis was done in a blinded fashion. Unless 
otherwise stated, all values are expressed as 
mean ± standard error of the mean (SEM) of n 
observations. Unless otherwise stated, the results 
were analyzed by ANOVA followed by a Bonferroni 
post-hoc test for multiple comparisons using 
GraphPad Prism 6 software. A value of P < 0.05 was 
considered significant. 
Results  
Selection of genes encoding candidate targets 
First, we identified genes of interest that are 
associated with the anti-inflammatory activation state 
of microglia. Candidate genes were selected based on 
the following three selection criteria: i) the level of 
expression of the candidate mRNA in the 
anti-inflammatory state had to be at least two-fold 
higher compared to the resting/surveilling state and 
to the pro-inflammatory activation state; ii) the genes 
had to be similarly regulated in rodents and humans; 
and iii) the genes had to be preferentially expressed in 
microglia. Genome-wide mRNA expression data 
published in the NCBI Gene Expression Omnibus 
database [33] (GSE5099 [34], GSE35449 [35], GSE57614 
[36], GSE36537 [37], GSE32164 [38], and GSE64498) 
were used to generate co-expression networks using 
the weighted correlation network analysis (WGCNA) 
package for R [39], a software package widely applied 
to evaluate common denominators in meta-analyses 
or disease models [33] and a powerful tool to integrate 
immunology with bioinformatics [40].  
We identified a set of genes expressed in human 
and murine samples and characterized by: 1) low 
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expression in unstimulated conditions and following 
pro-inflammatory (LPS) stimuli, and 2) high 
expression induced by anti-inflammatory stimuli (IL4, 
IL13). The genes were sorted based on the Log2-fold 
change in the expression (Log2FC) following the 
anti-inflammatory stimuli vs. the other treatments, 
and the 100 genes characterized by the highest Log2FC 
were further screened to select those meeting the 
following features: 3) cell surface expression rather 
than intracellular expression; 4) higher expression in 
microglia vs. macrophages (or other neural cell types); 
5) available literature on small molecule compounds 
binding the encoded proteins (to be used for the 
development of a PET tracer). Based on these criteria, 
15 genes (Table 1) were selected, which were then 
further evaluated and ranked with a qualitative 
weight ranging from (+++) to (--) taking the chemical 
features of the proteins encoded by the 15 genes into 
consideration (availability of selective ligands with 
high affinity that are amenable to labeling with 
carbon-11 or fluorine-18) as well as their biological 
properties (membrane localization, expression levels 
in anti-inflammatory microglia vs. other brain cells, 
expression in murine and human microglia). Three 
priority groups (Tiers) were identified, and the genes 
in Tier 1 (P2ry12, Ramp1, and Calcrl) (Table 1) were 
validated in vitro and ex vivo in human and murine 
samples. 
 
Candidate target validation in human samples 
Human primary macrophage and microglia 
cultures were used to investigate the responsiveness 
of the selected markers to a 48 h exposure to 
anti-inflammatory (IL4, 20 ng/mL) and 
pro-inflammatory (LPS, 1 µg/mL) stimuli (Figure 
1A). In the macrophages, under all conditions, 
P2RY12 expression was below the lower limit of 
detection of the qPCR assay. This is in line with recent 
reports showing that P2RY12 expression 
distinguishes human microglia from peripheral 
monocytes, macrophages, and other immune cells [41, 
42]. Nevertheless, as Martinez et al. [34] and Beyer et 
al. [35] demonstrated that P2RY12 expression is 
induced in human macrophages upon GM-CSF or 
M-CSF stimulation, we tested GM-CSF and M-CSF (in 
a concentration of 100 ng/mL) after 48 h in the 
presence or absence of LPS (10 ng/mL) or rIL4 (20 
ng/mL). Figure S1 shows that the culture conditions 
including GM-CSF or M-CSF led to detectable levels 
of P2RY12 mRNA in unstimulated cells, and upon 
stimulation with rIL4, levels of P2RY12 mRNA 
increased significantly (35-fold). Regarding the other 
candidate genes, RAMP1 expression was significantly 
induced only following rIL4 treatment (40-fold and 
15-fold, Figure 1A and Figure S1). Moreover, a slight, 
but significant, increase (3-fold) in CALCRL mRNA 
was measured in rIL4-stimulated human 
macrophages (Figure 1A). In M-CSF-treated human 
macrophages, however, the observed increase of 
CALCRL was not significant (Figure S1). 
Table 1. List of 15 selected targets/genes 
Tier Rank Gene Membrane 
localization 
Microglia-specific 
expression 
Availability of 
selective 
ligands 
Described function in microglia Ref 
1 1 P2RY12/P2ry12 + +++ ++ Involved in microglial chemotaxis. 
Expression is enhanced in human microglia under anti-inflammatory 
activation conditions. Expression on human microglia is modulated in 
neuroinflammatory diseases. 
[62] 
[56] 
[53] 
2 RAMP1/Ramp1 + + ++ Exerts a potent inhibitory effect on LPS-induced microglia activation in 
vitro. Ramp1 deficiency dampens microgliosis in an ALS mouse model. 
[63] 
[64] 
3 CALCRL/Calcrl + + ++ Exerts a potent inhibitory effect on LPS-induced microglia activation in 
vitro. 
[63] 
2 4 QPCT/Qpct - ++ ++ Qpct inhibition results in a reduced microglial activation around 
amyloid plaques in transgenic AD Tg2576 mice. 
[65] 
5 P2RY14/P2ry14 + - + UDP-activated receptor. [66] 
6 HMOX1/Hmox1 - ++ + Dampens inflammatory reactions. [67] 
7 CXCR4/Cxcr4 + + + Involved in microglia migration. [68] 
8 HRH1/Hrh1 + - +++ H1R signaling in CD11b+ cells can modulate cytokine production by 
macrophages upon LPS stimulation. 
[69] 
9 MMP12/Mmp12 (+) ECM + + MMP12 deficiency increases the inflammatory activity of adult 
brain-derived microglia. 
[41] 
10 PTGER2/Ptger2 + -- - PGE2-activated Ptger2 regulates innate immunity in the CNS. [70] 
11 PPP1R14A/Ppp1r14a - -- - Upregulated in human Th2-polarized T helper cells. [71] 
3 12 TBXAS1/Tbxas1 + ++ --   
13 GPD1L/Gpd1l - + --   
14 ABAT/Abat - -- --   
15 HS2ST1/Hs2st1 + - --   
Legend of symbols. Membrane localization: +, yes; -, no. Microglia-specific expression (vs. other CNS cells): +, > 2-fold expression; ++, > 5-fold expression; +++, > 10-fold 
expression; -, no differences; --, under-expressed. Availability of selective ligands: +, ligands already available; ++, different options already available; +++, many ligands 
available; -, no viable ligands available; --, no ligands available. 
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Figure 1. Evaluation of P2RY12, RAMP1, and CALCRL mRNAs in human samples. (A) qPCR analysis of P2RY12, RAMP1, and CALCRL mRNA accumulation 
in primary human macrophage cultures, 48 h post vehicle, LPS, or rIL4 treatments. Data are expressed as 2-ΔΔCt using the 36B4 transcript as an internal reference 
standard. Bars represent the mean ± SEM of 3 independent experiments done in triplicate. N.D., not determined. (B) qPCR analysis of P2RY12, RAMP1, and CALCRL 
mRNA accumulation in primary cultures of human microglia, 48 h post vehicle, LPS, or rIL4 treatments. Data are expressed as 2-ΔΔCt using the 36B4 transcript as an 
internal reference standard. Bars represent the mean ± SEM of 3 independent experiments done in triplicate. *, P < 0.05; ***, P < 0.001 by two-way ANOVA vs. 
vehicle. 
 
 
In primary human microglia cells (Figure 1B), 
LPS stimulation had no effect on the expression of the 
selected markers. On the other hand, rIL4 induction 
led to a remarkable increase in P2RY12 (393-fold) and 
CALCRL (81-fold) mRNAs levels. These data provide 
evidence that the investigated genes are good 
indicators of anti-inflammatory microglia activation 
in human samples. 
In vivo induction of the microglial anti- 
inflammatory activation state 
To induce the anti-inflammatory activation state 
in microglial cells in vivo, murine rIL4 (100 ng) in 
saline (3 µL) was injected icv in adult male mice. The 
effectiveness of the treatment was confirmed 16 h 
after injection by measuring Ym1 mRNA, a 
well-known marker of anti-inflammatory microglia in 
mice [22]. A 28-fold increase in Ym1 mRNA 
expression was measured in whole brain lysates (see 
Figure 2A) in icv rIL4-injected mice compared to 
vehicle-injected mice. Further analysis of microglial 
cells sorted from adult (3-month-old) mice showed 
that the Ym1 induction (33-fold) took place in 
CD11b-positive cells (Figure 2B). In contrast, brain 
cells other than microglia showed very low levels of 
Ym1 mRNA prior to and after rIL4 treatment (Figure 
S2), further demonstrating that Ym1 mRNA in 
microglia was expressed at much higher 
concentrations than in other neural cells. Thus, the 
induction of Ym1 observed in the whole brain samples 
after IL4 icv treatment is attributable to microglia with 
an anti-inflammatory activation state. Measurement 
of Ym1 mRNA in specific brain areas (cortex, 
hippocampus, and hypothalamus, Figure 2C) showed 
that the rIL4 icv injection induced the 
anti-inflammatory activation of microglia in the 
selected brain areas, resulting in a very strong 
increase of Ym1 in both cortex (48-fold) and 
hippocampus (67-fold), and a mild induction in the 
hypothalamus (8-fold). Based on these results, the 
same protocol was applied in the subsequent 
experiments. 
Candidate target validation in the mouse brain 
Next, the expression of the first tier of genes 
identified by the computational analysis (Table 1) 
was verified in the aforementioned model. Consistent 
with the findings of the whole genome analyses, the 
levels of these genes appeared to be 
induced/increased after the icv rIL4 treatment, with 
different expression profiles depending on the 
considered brain area (Figure 2C). In detail, P2ry12 
was maximally induced in the cortex (1.65-fold), Calcrl 
in the hippocampus (4.13-fold) and Ramp1 was 
induced similarly in the three analyzed brain regions 
(cortex, 1.87-fold; hippocampus, 2.21-fold; 
hypothalamus, 1.81-fold). These results demonstrate 
that the selected genes are sensitive to rIL4 treatment 
in vivo and are useful as markers for the 
anti-inflammatory activation state of microglia in 
adult mice. Under basal conditions, the content of 
P2ry12 mRNA was higher (35-fold) in freshly isolated 
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adult microglia than in other brain cells. In contrast, 
the amounts of Ramp1 and Calcrl mRNAs were 
comparable in isolated microglia and in brain cells 
depleted of microglia (Figure S3). Upon icv injection 
of rIL4, the mRNA expression of the three candidate 
markers was increased in microglia (Figure 2D; 
2.11-fold P2ry12; 1.71-fold Ramp1; 1.51-fold Calcrl).  
 
Figure 2. Evaluation of P2ry12, Ramp1, and Calcrl mRNAs in murine samples. (A) qPCR analysis of Ym1 mRNA expression 16 h post icv injection of rIL4. 
C57BL/6 mice (n = 3) were injected with 100 ng mouse rIL4 or vehicle. mRNA expression of Ym1 in whole brain lysates was measured by quantitative RT-PCR and 
data are expressed as 2-ΔΔCt using the 36b4 transcript as an internal reference standard. Bars represent mean ± SEM of 3 independent experiments done in triplicate. 
(B) Ym1 mRNA was measured in microglia acutely isolated from whole brains of C57BL/6 mice (n = 3) 16 h after rIL4 (IL4, 100 ng) or vehicle (veh) icv injection; data 
were calculated and are expressed as in the previous figure. Bars represent the mean ± SEM of 3 independent experiments done in triplicate. (C) C57BL6 mice (n = 
3) were injected with 100 ng mouse rIL4 or vehicle. Ym1, P2ry12, Ramp1, and Calcrl mRNA content of lysates from three brain areas (cortex, left panel; hippocampus, 
central panel; hypothalamus, right panel) was measured by quantitative RT-PCR and data are expressed as 2-ΔΔCt using the 36B4 transcript as an internal reference 
standard. Bars represent the mean ± SEM of 3 independent experiments done in triplicate. *, P < 0.05; **, P < 0.01 by two-way ANOVA vs. vehicle. (D) P2ry12, 
Ramp1, and Calcrl mRNAs were measured in microglia acutely isolated from whole brains of C57BL/6 mice (n = 3) mice 16 h after rIL4 (IL4, 100 ng) or vehicle icv 
injection. mRNA content of whole brain lysates was measured by quantitative RT-PCR and data are expressed as 2-ΔΔCt using the 36B4 transcript as an internal 
reference standard. Bars represent the mean ± SEM of 3 experiments done in triplicate. *, P < 0.05; **, P < 0.01 by two-way ANOVA vs. vehicle. 
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Figure 3. rIL4 induces P2RY12 expression in the rat brain. (A) IHC staining in the rat striatum for CD11b (red), CD206 (green), and DAPI (blue) following 
treatments with vehicle (left panel) or rIL4 (right panel). Representative images of n = 3 experiments are shown. Magnification: 20x. (B) IHC staining in the rat 
striatum for Iba1 (red), P2RY12 (green), and DAPI (blue) following treatments with vehicle (left panel) or rIL4 (right panel). Representative images of n = 3 
experiments are shown. Magnification: 20x. Scale bars: 20 µm. 
 
 The high specificity for microglial cells vs. other 
brain cells and macrophages, and the high and 
consistent induction in mouse in vivo and in human 
microglia in vitro suggested P2ry12/P2RY12 as a 
promising translational target for PET imaging of the 
anti-inflammatory activation state of microglia. 
Therefore, subsequent experiments focused on further 
validation of this marker and additionally on the 
development of novel PET tracers for application in 
pre-clinical and clinical in vivo imaging. 
Validation of P2RY12 in the rat brain 
To extend the study to other pre-clinical animal 
models, P2RY12 expression was also studied in rat 
microglia. To this purpose, vehicle or rat rIL4 (1 µg) 
were injected into the striatum of male Wistar rats. 
The expression levels of CD11b, Iba1, CD206 (a 
prototypical marker for the anti-inflammatory 
activation state), and P2RY12 were determined by 
IHC in brain sections collected 1 day post-injection. 
The specificity of the antibodies labeling CD206 and 
P2RY12 was confirmed by a negative control staining 
(without the first antibodies) in sections of 
rIL4-injected rats (Figure S4). CD11b and Iba1 
positive cells were found in both rIL4-treated and 
sham-operated rats (Figure 3A-B). IHC for CD206 
showed a clear signal on the ipsilateral site in 
rIL4-injected animals, but not in sham-operated 
animals, thus confirming that the treatment induced 
the expected microglial activation state in different 
species (Figure 3A). IHC for P2RY12 in the same 
rIL4-treated and sham-operated animals showed a 
strong staining in the brains of rIL4 animals (ipsi- and 
to a lesser extent contra-lateral). A faint signal was 
detected in the brains of sham-operated animals 
(Figure 3B). Nearly all P2RY12-positive cells also 
stained positively for Iba1. These results substantiate 
the hypothesis that increased P2RY12 expression can 
be considered as a reliable and translational marker 
for the anti-inflammatory activation state of microglia. 
Evaluation of P2RY12 expression in rodent and 
human brain after stroke 
Inflammation is considered as a key factor 
involved in brain tissue damage in response to stroke 
[43, 44]. Increasing evidence suggests that following 
the inflammatory phase induced by the ischemia, 
myeloid cells acquire an anti-inflammatory activation 
state that is believed to play a role in the tissue repair 
process [43, 45]. Experimental evidence showed that 
microglia start expressing anti-inflammatory markers 
as early as 24 h after pMCAO [46]. At later times, the 
expression of most pro-inflammatory markers is 
reduced, while the expression of anti-inflammatory 
markers increases in parallel with tissue repair [46]. 
Accordingly, mice that lack appropriate signals for 
anti-inflammatory induction have worse outcomes 
after experimental cerebral ischemia [47]. With this in 
mind, we investigated the expression of P2ry12 in the 
infarct region of mice subjected to MCAO, thus 
detecting a decrease in its expression in the affected 
hemisphere compared with the unaffected 
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hemisphere (Figure S5). Analogously, in rats, IHC 
stainings performed on brain tissue collected 48 h 
after pMCAO surgery show that immunoreactivity of 
P2RY12 was constitutively present in the unaffected 
areas (Figure 4A). Consistently with the reported 
evidence of an upregulation of anti-inflammatory 
activation markers, P2RY12 expression was higher in 
ramified microglia located at the border of the 
damaged area than those present in the core of 
infarction (Figure 4A). Since IHC results were 
comparable in both species after pMCAO further 
experiments were focused on one rodent species 
(mice). 
To verify P2RY12 expression in response to 
stroke in human, tissue sections of stroke patients 
were collected post-mortem in a time window from 6 
to 18 days after stroke. P2RY12 was expressed in 
human microglia of control tissues. Consistent with 
prior observations in the rat model, in the core of the 
infarction site, containing round myeloid cells, 
P2RY12 immunoreactivity was lower than in the 
ramified microglia located at the border of the lesion 
(Figure 4B). These results further support P2RY12 as a 
potential marker for the anti-inflammatory activation 
state, characteristic of the recovery phases of stroke in 
both murine and human brains. The body of evidence 
collected led us to proceed with the design and 
development of a novel PET tracer targeting P2RY12. 
Development of a PET tracer targeting 
P2RY12 
Following a literature search for compounds 
with high affinity towards P2RY12, a compound (5, 
IC50 of 6 nM, Figure 5) amenable to radiolabeling with 
carbon-11, was selected from a series of highly potent 
P2RY12 antagonists reported by Bach et al. [48]. 
Precursor 3 was synthesized as described by Bach et 
al. (Figure 5); sulfonylurea 5 was obtained by in situ 
formation of the sulfonylisocyanate starting from 
sulfonamide 4, and the subsequent addition of 
azetidine-amine 3. Sulfonylazide precursor 6 was 
obtained by reaction of sulfonamide 4 with freshly 
prepared triflyl azide. [11C]5 was obtained from 
precursors 3 and 6 via a rhodium-mediated carbon-11 
carbonylation reaction [49, 50] in THF, using 
[Rh(COD)Cl]2 as rhodium source and 
triphenylphosphine as ligand. Azide 6 co-eluted with 
[11C]5 on semi-preparative high performance liquid 
chromatography (HPLC), therefore, remaining azide 
6 was reduced to sulfonamide 4 using ≥ 2 equivalents 
of tris(2-carboxyethyl)phosphine (TCEP), to facilitate 
a less complicated purification. The quenched 
reaction mixture was subjected to semi-preparative 
HPLC and the collected fraction was formulated to 
obtain [11C]5 (705–1160 MBq) with sufficient 
radiochemical purity (> 98%) and molar activity (79 ± 
32 GBq/μmol; n = 6) to be evaluated in vitro and in 
vivo. Formulated [11C]5 was determined to be stable 
up to 2 h after synthesis by analytical HPLC. 
 
 
Figure 4. P2RY12 expression is induced after ischemic stroke. (A) Immunostaining of P2RY12 (in green) and DAPI (in blue). Upregulation of P2RY12 
expression in ipsilateral brain section surrounding the ischemic core (dotted line). Forty-eight h after pMCAO surgery, P2RY12 expression is increased in the outer 
border of the ischemic lesion (asterisk), while it is downregulated in the core of the ischemic lesion (pound sign). Scale bar: 1 mm. Inlet: T2W MRI taken at the same 
anatomic level. (B) Immunostaining of P2RY12 (in green) and TO-PRO-3 (in blue). P2RY12 expression in the infarct region (left panel) or in the non-affected region 
(right panel) of post-mortem tissue sections of stroke patients deceased 15 days after stroke. Representative images of n = 2 experiments are shown. Top: 20x 
magnification, scale bar: 30 µm. Bottom: 63x magnification, scale bar: 10 µm. 
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Validation of novel PET tracer [11C]5 
Determination of LogDoct,7.4 
The LogDoct,7.4 of [11C]5 was determined to be 
1.93 ± 0.02 using the shake-flask method (partitioning 
between 1-octanol and 0.2 M phosphate buffer; pH 
7.4). 
Ex vivo biodistribution 
Healthy male Wistar rats were injected with 30 ± 
13 MBq of [11C]5, and subsequently sacrificed at 5 min 
(n = 4) or 15 min (n = 3) after tracer injection to study 
the distribution of the tracer in vivo (Figure 6A), with a 
main focus on tracer uptake in the brain. Although 
P2RY12 is expressed on blood platelets, which could 
hamper microglia imaging, [11C]5 showed little 
retention in the blood. [11C]5 showed no abnormalities 
in peripheral biodistribution; clearance occurred via 
kidney and liver. However, no brain uptake of [11C]5 
was observed (< 0.03% ID/g), likely due to poor 
passage across the blood-brain barrier (BBB).  
Metabolite analysis 
To assess the in vivo stability of [11C]5, 51 ± 2 MBq 
of the tracer was administered to healthy male Wistar 
rats (n = 3) and 15 min after tracer injection, blood was 
drawn, and brains were excised. The amount of intact 
[11C]5 was 27% in plasma, at 15 min after injection 
(Table 2). Only a low percentage of polar metabolites 
was found, and HPLC analysis showed one major 
non-polar metabolite, which is believed to be the 
carboxylic acid, as esterases are known to rapidly 
cleave the ester moiety in vivo [51]. Metabolites in 
brain could not be determined due to lack of brain 
uptake of [11C]5. 
In vitro autoradiography 
To validate the binding of [11C]5 to P2RY12, 
sections of both vehicle-injected mouse brain and 
rIL4-injected mouse brain (sacrificed 16 h post 
injection) were incubated with a buffer solution of 
[11C]5 (10 nM), as well as with the same tracer solution 
containing the non-structurally related P2RY12 
antagonist ticagrelor (10 µM). Specific binding to 
P2RY12 was observed, as binding could be blocked 
significantly with ticagrelor in all brain sections 
(Figure 6B). Binding of [11C]5 was 1.4-fold higher in 
the rIL4-injected mouse brains compared with 
vehicle-injected mouse brains, confirming the 
upregulation of P2RY12 in these conditions. 
Autoradiography experiments were also performed 
on mouse brain sections of mice unilaterally subjected 
to tMCAO. Relative binding of [11C]5 was found to be 
significantly decreased in the affected hemisphere 
compared with the unaffected hemisphere at all time 
points after the procedure (3 d: 69 ± 22%; 7 d: 83 ± 
11%; 10 d: 78 ± 22%) (Figure 6C-D). 
 In addition, a similar autoradiography 
experiment was performed on post-mortem human 
brain sections of a stroke patient. [11C]5 showed less 
binding in the stroke core compared with the 
contralateral tissue. Immunofluorescence staining 
was performed on the same tissue after 
autoradiography to evaluate P2RY12 expression and 
microglia activation. Immunostaining showed higher 
expression of P2RY12 on microglia in contralateral 
tissue compared with stroke core tissue, which 
correlates with the binding of [11C]5 observed in 
autoradiography (Figure 6E and Figure S6).  
 
Table 2. Metabolite analysis results of [11C]5 in plasma (n = 3). 
 15 min (%) 
Intact tracer 27 ± 11 
Non-polar metabolite(s) 70 ± 10 
Polar metabolites 3 ± 1 
 
 
Figure 5. Development of a novel PET tracer targeting P2RY12. Synthesis route towards P2RY12 antagonist 5, precursors 3 and 6, and [11C]5. Reagents 
and conditions: a) 3-(Boc-amino)azetidine, DiPEA, 1,2-dichloroethane, 60 °C, 1 h, 32%; b) HCl (4 M in 1,4-dioxane), CH2Cl2, 30 min, 87%; c) Chlorosulfonyl 
isocyanate, 1,2-dichlorobenzene, 160 °C, 2 h; d) 3, MeCN, 16 h, 45% (over 2 steps); e) TfN3, K2CO3, CuIISO4, CH2Cl2/MeOH/H2O, 16 h, 88%; f) 3, [11C]CO, 
[Rh(COD)Cl]2, PPh3, THF, 100 °C, 5 min, 10 ± 2% (radiochemical yield, decay corrected). 
 Theranostics 2018, Vol. 8, Issue 19 
 
 
http://www.thno.org 
5415 
 
Figure 6. Validation of a novel PET tracer targeting P2RY12. (A) Ex vivo biodistribution following intravenous injection of about 30 MBq of P2RY12 PET 
tracer [11C]5 in healthy male Wistar rats (n = 4 for 5 min; n = 3 for 15 min). Data are expressed as percentage injected dose per gram of tissue (%ID/g). (B) 
Percentages of [11C]5 binding, relative to binding to brain tissue of vehicle injected mice (sacrificed 16 h p.i.). [11C]5 binding was shown to be 1.4-fold higher on 
average (n = 4). Binding could be blocked significantly with a non-structurally related P2RY12 antagonist (ticagrelor, 10 µM), indicating specific binding of [11C]5 to 
P2RY12. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (unpaired t-test, two-tailed). (C) Autoradiograms of mouse brains 3, 7 and 10 days post unilateral tMCAO procedure 
with affected ipsilateral (i) and unaffected contralateral (c) hemisphere indicated. Sections are from 2 different mice per time point. (D) Quantification of [11C]5 
binding in AR experiments. Binding is expressed as percentage relative to tracer binding in the contralateral (c), unaffected hemisphere. Bars represent the mean ± 
SD of 2 different mice per time point, 5 sections per condition. (E) Human stroke and contralateral tissues stained post-autoradiography with rabbit anti-P2Y12 
antibody (green), mouse anti-MHCII (clone LN3) (red), and DAPI (blue). Merge shows co-localization of P2RY12 with microglia stained with anti-MHCII. 
Discussion  
Because of its major involvement in several 
neurological and neuropsychiatric disorders, the 
function of microglia in neuroinflammation raised 
considerable interest in recent years. The lack of 
suitable tools to study these multifaceted cells 
currently represents a major obstacle for the 
progression of the understanding of the exact role 
played by these cells in healthy and diseased people 
and, therefore, their potential as a therapeutic target. 
The aim of this work was to identify and validate 
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novel markers that allow for studying the 
anti-inflammatory activation state of microglia, which 
is believed to be associated with the ability of 
microglia to conclude the inflammatory phase and to 
exert reparative functions. We identified three genes 
encoding for the proteins P2RY12, RAMP1 and 
CALCRL, which may represent novel and 
translational markers, since they are specifically 
expressed in microglial cells and regulated by 
anti-inflammatory stimuli both in humans and 
rodents.  
P2RY12 was found to be of particular interest 
due to its high and restrictive expression in microglia 
in the CNS, which provides the ability to distinguish 
microglia from other peripheral immune cells [41, 42, 
52, 53]. P2RY12 is a G-protein-coupled purinergic 
receptor originally discovered in platelets [54], where 
it is involved in aggregate formation in response to 
vessel injury [55]. Therefore, multiple compounds 
with high affinity for P2RY12, originally developed as 
anticoagulants, have been reported, which could 
serve as a starting point for the development of novel 
molecular imaging agents. P2RY12 is downregulated 
in the pro-inflammatory activation state of microglia 
[56], which is in line with our findings showing that 
the expression of P2RY12 is very low when microglia 
are treated with the inflammatory stimulus LPS. Here 
we provide evidence that P2RY12 expression is 
associated with the exposure to anti-inflammatory 
stimuli in cells of human and murine origin and, more 
importantly, that P2RY12 protein expression is 
modulated in the reparative phase of experimental 
and clinical stroke. Our study significantly extends 
what was published by Moore et al. [56] on P2RY12 
responsiveness to M-CSF, IL4, and IL13. In 
conclusion, P2RY12 is a potential novel target for 
quantitative PET imaging allowing analysis of the 
dynamics of anti-inflammatory microglia activity in 
living subjects.  
As a first attempt towards our aim of developing 
PET tracers for imaging anti-inflammatory microglia, 
we successfully synthesized the first PET tracer 
targeting P2RY12, [11C]5, which enabled us to 
visualize the binding of the tracer to its target with 
less than 1 h exposure compared to tritium-labeled 
radiotracers that require 6-8 weeks of film emulsion 
exposure or 5-7 days exposure for phosphor imaging. 
In spite of the relatively low resolution of the 
carbon-11 labeled ligand, we were able to show a 
significant increase of [11C]5 binding to brain sections 
of mice treated icv with IL4 and low binding of [11C]5 
to human brain sections of a patient deceased after 
stroke. These results correlate well with the [11C]5 
binding observed in a stroke model in mice, where a 
decreased binding was observed at all time points (3, 
7 and 10 days) after tMCAO in the lesioned 
hemisphere, which was most pronounced at 3 days 
after tMCAO. The binding of [11C]5 observed in all 
tissues was blocked by co-incubation with ticagrelor, 
indicating specific binding of [11C]5 to P2RY12. 
Although the increase in P2RY12 induced by 
anti-inflammatory treatment with IL4 was on the 
lower side, the possibility to show this increase using 
tracer binding in autoradiography experiments holds 
promise for future tracer applications. Even though 
an increase in P2RY12 signal was shown at the border 
of the stroke lesion using IHC, we were unable to 
show this effect in autoradiography studies due to 
restrictions in signal resolution of this technique in 
mouse brains and limited availability of suitable 
tissue sections from humans. Therefore, further 
experiments are required to determine whether the 
increase in P2RY12 expression at the stroke border 
region is sufficient to detect with PET imaging in vivo 
in human patients. Since P2RY12 is also 
downregulated under pro-inflammatory conditions, 
as we consistently detected in the stroke core in 
rodent and human tissue, an alternative would be to 
quantify the decrease in P2RY12 signal in the affected 
regions. Because of its opposite regulation by pro- and 
anti-inflammatory stimuli, we expect to be able to 
quantify differences in P2RY12 tracer uptake in 
different brain regions in human CNS pathologies; 
this, however, has to be tested in future experiments. 
Interestingly, a modulation in P2RY12/P2ry12 
expression has been reported in the brain of 
Alzheimer’s disease animal models [57] and multiple 
sclerosis animal models as well as patients [58], and a 
reduction in its expression levels has recently been 
linked to a particular microglial phenotype, 
specifically associated with neurodegenerative 
diseases [59]: this body of evidence supports the 
relevance of a P2RY12 tracer for the study of 
neurodegenerative diseases. 
Unfortunately, in vivo studies did not show 
presence or accumulation of the tracer in the rat brain 
which indicates that the tracer did not cross the BBB. 
The lipophilicity (LogDoct,7.4 = 1.93 ± 0.02), of this 
tracer is compatible with passive diffusion through 
the BBB; however, it is likely that [11C]5 is too polar to 
allow for this, and, in addition, it could be speculated 
that this tracer is a substrate for the brain efflux 
transporter P-glycoprotein (P-gp). This hypothesis is 
supported by the high uptake of [11C]5 in duodenum, 
where P-gp actively transports substrates from the 
blood into the intestine [60, 61]. Moreover, we found 
that the metabolic stability of [11C]5 was not optimal 
for a PET tracer since only 27% of intact compound 
was still available in the blood after 15 min. Thus, we 
can conclude that [11C]5 is not suited for in vivo PET 
 Theranostics 2018, Vol. 8, Issue 19 
 
 
http://www.thno.org 
5417 
imaging, and it would be advisable to look into a 
different class of compounds for this purpose. 
However, the developed tracer may still be useful for 
in vitro studies, and the first results with [11C]5 in 
post-mortem human brain warrant the pursuing of 
the P2RY12 receptor as a target for PET imaging of 
neuroinflammation.  
Conclusion 
This study shows the potential of a 
rationale-based approach for the identification of new 
targets that can be used to design PET tracers. We 
believe that the value of the present study is to prove 
the validity of a methodology that can be applied to 
the rapid analysis of data available in the literature for 
the identification of novel biomarkers. In addition, we 
believe that our study will serve an important 
function in the field of neuroinflammation by 
providing novel and translational biomarkers for the 
generation of PET tracers of the anti-inflammatory 
activation state of microglia. Pre-clinical and clinical 
implementation of these new tracers will certainly 
improve our knowledge of the dynamics of the 
neuroinflammatory processes in aging and 
neurodegenerative diseases, and will provide new 
specific, measurable endpoints for the early 
assessment of therapeutic efficacy in various 
neurological diseases. 
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